Alkermes
plc ALKS today announced that the United States Patent and
Trademark Office (USPTO) has issued a Notice of Allowance for U.S.
Patent Application 12/823,007, titled “Heterocyclic Compounds for the
Treatment of Neurological and Psychological Disorders.” The allowed
claims will cover a class of compounds that includes aripiprazole
lauroxil, a proprietary Alkermes molecule formerly referred to as ALKS
9070, which is in development for the treatment of schizophrenia.
Aripiprazole lauroxil is designed to provide patients with once-monthly
dosing of a medication that, once in the body, converts into
aripiprazole, a molecule that is commercially available under the name
ABILIFY® for the treatment of a number of central nervous
system (CNS) disorders.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in